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ABSTRACT
Objective To evaluate the effects of drug interventions 
that may modify the progression of chronic kidney disease 
(CKD) in adults with CKD stages 3 and 4.
Design Systematic review and meta-analysis.
Methods Searching MEDLINE, EMBASE, Database of 
Abstracts of Reviews of Effects, Cochrane Central Register of 
Controlled Trials, Cochrane Database of Systematic Reviews, 
International Clinical Trials Registry Platform, Health 
Technology Assessment, Science Citation Index, Social 
Sciences Citation Index, Conference Proceedings Citation 
Index and Clinical Trials Register, from March 1999 to July 
2018, we identified randomised controlled trials (RCTs) of 
drugs for hypertension, lipid modification, glycaemic control 
and sodium bicarbonate, compared with placebo, no drug 
or a drug from another class, in ≥40 adults with CKD stages 
3 and/or 4, with at least 2 years of follow-up and reporting 
renal function (primary outcome), proteinuria, adverse 
events, maintenance dialysis, transplantation, cardiovascular 
events, cardiovascular mortality or all-cause mortality. Two 
reviewers independently screened citations and extracted 
data. For continuous outcomes, we used the ratio of means 
(ROM) at the end of the trial in random-effects meta-
analyses. We assessed methodological quality with the 
Cochrane Risk of Bias Tool and confidence in the evidence 
using the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) framework.
Results We included 35 RCTs and over 51 000 patients. 
Data were limited, and heterogeneity varied. Final renal 
function (estimated glomerular filtration rate) was 6% 
higher in those taking glycaemic control drugs (ROM 1.06, 
95% CI 1.02 to 1.10, I2=0%, low GRADE confidence) and 
4% higher in those taking lipid-modifying drugs (ROM 
1.04, 95% CI 1.00 to 1.08, I2=88%, very low GRADE 
confidence). For RCTs of antihypertensive drugs, there 
were no significant differences in renal function. Treatment 
with lipid-modifying drugs led to a 36% reduction in 
cardiovascular disease and 26% reduction in all-cause 
mortality.
Conclusions Glycaemic control and lipid-modifying drugs 
may slow the progression of CKD, but we found no pooled 
evidence of benefit nor harm from antihypertensive drugs. 
However, given the data limitations, further research is 
needed to confirm these findings.
PROSPERO registration number CRD42015017501.
InTRODuCTIOn
Chronic kidney disease (CKD) is a long-term 
loss of renal function and is a global health 
problem, with an estimated prevalence of 
11%–13%.1 CKD is an independent risk factor 
for cardiovascular disease,2 and people with 
mild-to-moderate CKD are at increased risk 
of mortality and progression to renal failure.3
Historically, CKD was categorised by its 
cause, which was predominantly diabetes, 
Strengths and limitations of this study
 ► By focusing on patients with chronic kidney disease 
(CKD) stages 3 and 4, we provide a primary care 
perspective on the management of CKD.
 ► We completed an extensive and comprehensive 
search including common drug mis-spellings, with 
no restriction on language or publication type.
 ► Generalisability of our findings is limited by the 
paucity of trials, high statistical heterogeneity, high 
clinical heterogeneity, in terms of comorbidities and 
by the effect of drugs on CKD being secondary in all 
the studies.
 ► Lack of data restricted our ability to explore the 
baseline characteristics of studies, the effects of 
drugs, and the link between treatment effect and 
drug dose, and assess the potential for publication 
bias.
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hypertension, glomerulonephritis or polycystic kidney 
disease. Treatment could be recommended, but often 
opportunities were missed for early detection of the 
disease or prevention of clinical complications and 
further deterioration. The National Kidney Founda-
tion addressed this challenge by developing a five-stage 
classification system based on the glomerular filtration 
rate (GFR) (online supplementary material),4 which 
was subsequently modified to take into account degrees 
of proteinuria (online supplementary material).5 A UK 
audit in 2012 estimated that 90% of cases of CKD are at 
stage 3, and of these 84% are at stage 3a (estimated GFR 
(eGFR) 45–59 mL/min/1.732).6
Patients with CKD who are managed in primary care 
include those in stages 1 and 2, with an emphasis on 
lifestyle and diet changes. Patients in stages 3 and 4 may 
be managed either in primary care or shared care with 
specialist nephrology services, with a greater use of medi-
cation, primarily for associated long-term conditions, 
such as diabetes and hypertension. Both published data 
for Oxfordshire7 and unpublished national data from 
our group show that some patients with CKD stage 4 have 
their renal function monitored in primary care.
Four different classes of drugs may modify CKD progres-
sion: antihypertensives,8 lipid-modifying drugs,9 glycaemic 
control medications in patients with diabetes10 and 
sodium bicarbonate.11–13 Sodium bicarbonate addresses 
metabolic acidosis, a prevalent complication in moderate 
and late-stage CKD, and may offer a simple and low-cost 
treatment to slow CKD progression. The effects of drugs 
on CKD are secondary, as these drugs are primarily used 
to treat hypertension, hypercholesterolaemia or diabetes.
Systematic reviews have been compiled to summarise 
the effects of drug interventions on the rate of CKD 
progression.9 10 14–16 However, while two have reported 
results based on eGFR, none has reported results with 
reference to CKD staging. Furthermore, no systematic 
review has compared the effects of different drug classes.
Our objective was to carry out a systematic review and 
meta-analysis of randomised controlled trials (RCTs) to 
examine and compare the effects on the progression of 
CKD of the four classes of drugs, focusing on patients 
who can be managed in primary care or shared care with 
specialist nephrology services.
METhODS
Our systematic review protocol was registered with PROS-
PERO (International Prospective Register of Systematic 
Reviews) and reported in line with the recommenda-
tions from the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses statement.17
Search strategy
The search strategy was designed by an information 
specialist (NR) with advice from clinicians including 
nephrologists. Medical Subject Headings (MeSH) 
terms included terms for population, study design and 
intervention drugs (randomised control trials, chronic 
kidney, renal, drug classes and specific drug names, 
including common mis-spellings). Our included drug list 
is shown in the online supplementary material.
Searches were conducted in Ovid MEDLINE (online 
supplementary material), Cochrane Central Register 
of Controlled Trials, Cochrane Database of Systematic 
Reviews, Database of Abstracts of Reviews of Effects, 
EMBASE, Health Technology Assessment, Science Cita-
tion Index, Social Sciences Citation Index, Conference 
Proceedings Citation Index, Clinical Trials Register, and 
the WHO International Clinical Trials Registry Platform 
to 6 July 2018 to identify relevant studies, regardless 
of their publication type. No language restriction was 
applied. All publications from March 1999 onwards were 
considered, to align with the publication of the first equa-
tion to calculate eGFR, which had led to the introduction 
of CKD staging.18 Reference lists were also examined.
Study selection
Two reviewers (KST, JM, NP and SF; in pairs) reviewed 
the title and abstract of each reference and identified 
potentially relevant references. Considering the full texts 
of these studies, two reviewers independently selected 
studies to be included in the review using predetermined 
inclusion criteria. Disagreements about study inclusion 
were resolved by a third reviewer.
The following were our study inclusion criteria:
1. RCTs of drugs that may modify the progression of 
CKD: antihypertensives, lipid-modifying drugs, glycae-
mic control drugs and sodium bicarbonate.
2. Control arms were either given a placebo drug, no 
drug intervention or a comparator drug from one of 
the three other classes.
3. Adult participants.
4. Patients with stage 3 and/or stage 4 CKD. Studies ad-
ditionally including patients with stage 1 and/or stage 
2 CKD were also included to increase the number of 
potential studies, but we would expect the treatment 
effect to be overestimated in these studies, as patients 
with stage 1 and 2 CKD would respond better to treat-
ment.
5. Populations with at least 40 participants.
6. Follow-up of at least 2 years.
7. Publications reporting a quantitative summary of effect 
as a change from baseline, or an endpoint measure of 
at least one of seven prespecified outcomes.
i. Renal function, which could be measured by GFR, 
eGFR, creatinine clearance (CrCl) or estimated 
CrCl. This was our primary outcome of interest.
ii. Proteinuria, which could be measured by protein 
excretion rate (PER), protein creatinine ratio 
(PCR), albumin excretion rate (AER) or albumin 
creatinine ratio (ACR).
iii. Adverse events.
iv. Commencement of maintenance dialysis or kid-
ney transplantation.
v. Cardiovascular events.
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vi. Cardiovascular mortality.
vii. All-cause mortality.
We excluded trials that reported only data about popu-
lations that included people with CKD stage 5 to avoid 
underestimating the treatment effect, as we would expect 
stage 5 patients to have more comorbidities, which might 
lead to worse outcomes.
Data extraction and quality assessment
Data were extracted independently by two reviewers 
(KST, JM, NP and JYV; in pairs) using a data extraction 
form, which was piloted on a sample of five studies.
Extracted data included study details (setting, interven-
tion dose and frequency, follow-up period), information 
on study participants (age, gender, ethnicity, smoking 
status, blood pressure, CKD stage, existing comorbidi-
ties) and outcome data. For one study19 20 we extracted 
endpoint eGFR data from an earlier point than the 
longest follow-up as the patient numbers at the longest 
follow-up were so small (<7% of the population). We 
contacted study authors to seek clarification about data 
and to request data that could be included in our study.
The methodological quality of studies was assessed 
independently by two reviewers (KST, JM, NP and JYV; in 
pairs) using the Cochrane Risk of Bias Tool.21 This tool 
considers the method of random sequence generation 
and allocation concealment (selection bias), blinding 
of participants, personnel and outcomes (performance 
and detection biases), the levels and balance of missing 
outcome data (attrition bias), and completeness of 
reporting (selective reporting bias).
Disagreements about extracted data or methodological 
assessments were resolved by a third reviewer.
Data synthesis and analysis
We expected high statistical heterogeneity,22 but pooled 
data to give an indication of the average effect. We also 
pooled data when there were only two or three studies, 
although this could be potentially misleading, in order 
to give an indication of potential trends had there been 
more study data. We carried out random-effects analyses 
based on the DerSimonian and Laird method,23 assessed 
statistical heterogeneity using the I2 statistic and calcu-
lated approximate 95% prediction intervals to estimate 
the likely effects in a clinical setting24 using the methods 
of Higgins et al.25
For the continuous outcomes (renal function and 
proteinuria), we used a ratio of means (ROM)26 27 effect 
measure, which allowed us to combine data from trials 
that reported different measures of renal function or 
proteinuria in a single analysis. Using the ROM effect 
measure overcomes limitations of the well-established 
standardised mean difference (SMD),21 by providing units 
that are more easily interpreted than SDs, and avoiding 
the problems associated with presenting results with 
SDs, which can produce misleading results by deflating 
treatment effects for studies of heterogeneous popula-
tions and inflating treatment effects in homogeneous 
populations.28 We calculated the ROM as the ratio of the 
final eGFR in the intervention group to the final eGFR 
in the comparator group, so ROM >1 favoured the inter-
vention group for eGFR, where higher values are better 
than lower values. If a study of renal function reported 
reductions from baseline or rates of decline rather than 
endpoint data, we estimated the ROM of endpoints by the 
ratio of the reduction from baseline or rate of decline in 
the comparator group to that in the intervention group 
(the reciprocal) to ensure the direction of effect was 
consistent across all studies, as higher values of declining 
renal function are worse. ROM <1 favoured the inter-
vention group for the proteinuria outcomes (ACR, AER, 
PER, PCR), where higher values are worse.
For a few studies it was necessary to make further esti-
mates by approximating a mean using the median; esti-
mating SD from the IQR21; or estimating SE of ROM by 
imputation using the mean value of the known SEs of the 
other studies.
Meta-analysis was carried out on the log-transformed 
ROM and its SE. For the primary analysis, eGFR measured 
by the Modification of Diet in Renal Disease (MDRD) 
equation was selected over Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) data, as MDRD 
is the main equation advocated in clinical guidelines and 
CKD-EPI was not introduced until 20095 29; eGFR was also 
selected over CrCl. When analysing the effects of treat-
ments on proteinuria, we pooled data for PER, PCR, ACR 
and AER using a ROM effect measure. For the dichoto-
mous outcomes, we specified the relative risk (RR) as the 
effect measure.
We performed separate sensitivity analyses to ensure 
that our estimates of the effect of treatment in studies of 
patients with CKD stages 3 and 4 only (our main focus) 
were not sensitive to our choice of model, assumptions, 
quality of the studies, estimations made or our choices 
of data.
The following were the prespecified sensitivity analyses:
 ► Fixed-effect analyses based on the inverse-variance 
method were carried out for the continuous outcomes 
and based on the Mantel-Haenszel method for the 
dichotomous outcomes.30 31
 ► Excluding studies rated as low quality, which we 
defined as having a high risk of attrition bias or alloca-
tion concealment bias; studies rated as ‘unclear’ were 
not excluded.
 ► Excluding studies without intention-to-treat analysis. 
This was prespecified on the assumption that we would 
be dealing with primary studies of the progression of 
CKD, but as the studies were secondary or post-hoc 
this analysis was no longer relevant.
The following were further, standard set of sensitivity 
analyses:
 ► Excluding studies with estimates.
 ► Using more conservative estimates, considering those 
of the SE of ROM by imputing with the 75% percen-
tile value of the known SEs rather than the mean 
value, reflecting greater uncertainty.
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Figure 1 PRISMA diagram. PRISMA, Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses. CKD, 
chronic kidney disease; MDRD, Modification of Diet in Renal 
Disease.
 ► Using alternative data, considering CKD-EPI data 
instead of MDRD data, for studies that measured 
eGFR using both equations.
 ► Excluding studies that measured PCR and PER in the 
analysis of proteinuria, as urine albumin is a more 
accurate measure of glomerular damage.
 ► Excluding each individual study, one by one, to see if 
the level of heterogeneity depended on a particular 
study.
The following were post-hoc sensitivity analyses:
 ► Using the Hartung-Knapp-Sidik-Jonkman variance 
correction to calculate 95% CIs reflecting the uncer-
tainty in heterogeneity estimates.32–34
 ► Excluding studies with non-placebo controls.
Our prespecified subgroup analyses were by age (<65 or 
≥65 years), ethnicity, smoking status, intensity of interven-
tion, high blood pressure (≥140/90 mm Hg), low blood 
pressure (≤90/60 mm Hg), method of eGFR measure-
ment, degree of proteinuria in the renal function anal-
ysis, drug type within each drug class and by CKD stages 3 
and 4 separately. Heterogeneity was assessed using the I2 
statistic. Publication bias was explored using funnel plot 
analysis with contour plots.21 35
We used the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) framework21 to 
report the overall quality of evidence for the primary 
outcome (final eGFR). The certainty in the evidence for 
each outcome was graded as high, moderate, low or very 
low.
When describing the included trials, we refer to 
‘studies’ to encompass single trials and publications that 
report more than one trial. When reporting analyses of 
the effects of the drugs, we refer to populations as some 
studies reported data for CKD subgroups or dose-depen-
dent subgroups. All results of meta-analysis are displayed 
in forest plots and/or tabulated. Results are divided into 
those for studies of patients with CKD stages 3 and 4 only 
and studies of patients with CKD stages 3 and 4 mixed 
with patients with stages 1 and 2.
All analyses were carried out using STATA v.14.2,36 
except the risk of bias figures which were created in 
RevMan v.5.3.37
Patient involvement
Members of a patient and public involvement group were 
part of the Stakeholder Group and Steering Committee 
of the National Institute for Health Research (NIHR) 
Programme Grant that inspired this study. No patients 
or patient representatives were involved in setting the 
outcome measures, nor were they directly involved in 
developing plans for the design or implementation of 
the study. Three members of this group commented on 
our manuscript and we thank them for their help in the 
Acknowledgement section. A 1-day dissemination event 
is planned to report the results of all the studies funded 
by the NIHR Programme Grant, including this study. 
Members of the patient and public involvement group 
will be invited to this event.
RESulTS
Search results
Through database registry and hand searches, we identi-
fied 13 133 records (figure 1), of which 35 studies (51 155 
patients) satisfied our eligibility criteria.
Study characteristics
Most of the 35 studies reported data about a single trial, 
while 3 studies reported data about a pooled analysis of 
more than one trial.19 20 38–43 Of the 35 studies, 1 was from 
China,44 1 from Tasmania,45 3 from Japan,46–51 6 from 
USA/Canada,52–65 9 from Europe,13 66–78 either in single 
or multiple countries, and the other 15 studies were 
multinational (online supplementary material). Nine-
teen studies13 19 20 38–40 44 48–57 61–65 68–70 74 75 78–90 provided 
data for populations with CKD stages 3 and/or 4 only. 
These studies had between 108 and 3094 patients, and 
the mean or median follow-up was between 24 and 66 
months.
One study67 had a 2×2 factorial design involving an antihy-
pertensive drug and a lipid-modifying drug, and this study 
is included in our analysis of both antihypertensive drugs 
and lipid-modifying drugs. Another study had a 2×271 72 
factorial design involving two antihypertensive drugs and 
a lipid-modifying drug, and this study is only included in 
our analysis of lipid-modifying drugs because all patients 
received antihypertensives. The other 33 studies were 12 
studies of antihypertensives,16 38–40 44 46 47 52–57 66 67 79–83 91–98 
13 of lipid-modifying drugs,45 48–51 58–63 68–70 73–78 84–86 99–104 
6 of glycaemic control agents19 20 41–43 87–90 105–107 and 2 of 
sodium bicarbonate13 64 65 (online supplementary mate-
rial). Four studies45 58–60 73 102–104 had populations with 
CKD and no comorbidities highlighted, 27 studies had 
a single comorbidity, and 4 studies had more than one 
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Figure 2 ROM of estimated glomerular filtration rate at the 
end of the trials for antihypertensives versus comparator 
(boxes) and pooled estimates across studies (diamonds) 
calculated by the random-effects DerSimonian and Laird 
method, split by CKD stage. CHARMa and CHARMb, CKD 
stages 3 and 4, respectively, with estimated glomerular 
filtration rate measured by the MDRD equation. IDNTa, 
intervention is irbesartan; IDNTb, intervention is amlodipine. 
CKD, chronic kidney disease; MDRD, Modification of Diet in 
Renal Disease; ROM, ratio of means.
comorbidity. Comorbidities were cardiovascular in 19 
studies19 20 38–43 46–51 53 54 57 61–63 68–72 74–78 81–83 89–92 98–101; type 
II diabetes in 9 studies19 20 41–43 53–56 79 80 87–90 93–97 105–107 
(including all 6 studies of glycaemic control drugs); and 
a renal disorder or damage (idiopathic chronic glomeru-
lonephritis, advanced chronic renal insufficiency without 
diabetes, advanced autosomal dominant polycystic kidney 
disease, renal impairment and metabolic acidosis) in 7 
studies13 44 52 64–67 84–86 (online supplementary material). 
In 15 studies,13 45–47 61–67 71–73 76 77 91–99 107 the population 
analysed for our primary outcome was the whole trial 
population, and in the other 20 the population analysed 
was a subgroup of the trial population, reported as either 
a subgroup or post-hoc analysis (online supplementary 
material).
Baseline data were provided for the same popula-
tion as that included in our analyses for 19 of the 35 
studies13 45 49–51 58–70 73 76–80 84–88 91–98 107; for the other 16 
studies, baseline data were only provided for either a 
different subset of the trial population or the whole trial 
population (online supplementary material).
Risk of bias
We considered the methodological quality of all 35 
eligible studies (online supplementary material), based 
on the design of the trial(s) from which data were 
obtained. Eight studies19 20 44 71–73 84–88 98 105 106 were ranked 
with high quality as they had ‘Low’ risk of bias across all 
domains, and we rated one study76 77 as ‘High’ risk of bias 
for three domains and ‘Unclear’ across two domains. 
Most studies described their method of randomisation, 
but fewer studies were clear about how they concealed 
the group allocation and whether participants, personnel 
and outcome assessors were blinded. The risk of attrition 
bias was high in nearly a quarter of the studies.
We had sufficient data to consider the possibility of 
publication bias based on the primary outcome of renal 
function in those taking antihypertensive and lipid-modi-
fying drugs. The contour-enhanced funnel plots suggested 
possible publication bias, as few studies were in the area 
of non-significance (online supplementary material).
Renal function
Most of the available data were on eGFR.
The pooled ROM of eGFR for antihypertensive drugs 
versus comparators at the end of the studies is shown 
in figure 2. There was no significant effect in studies of 
populations with CKD stages 3 and 4, and heterogeneity 
between studies was substantial at 94% (yielding a predic-
tion interval of 0.79–1.34), and this was not attributable 
to a single study. Adding data from the studies of patients 
that included those with CKD stages 1 and/or 2 increased 
the benefit to the intervention group but not significantly. 
All except one study (Bianchi et al66) had placebo controls. 
All the sensitivity analyses produced similar results of no 
significant treatment effect and heterogeneity remained 
substantial (online supplementary material).
The only subgroup analysis that was possible, of those 
prespecified, was by drug type within the antihypertensive 
drug class. Among studies of CKD stages 3 and 4 only, 
there were no significant treatment effects within the 
different drug types (online supplementary material), 
except in the case of calcium channel blockers, where the 
endpoint eGFR was 14% higher in the intervention group 
(ROM 1.14, 95% CI 1.01 to 1.27), but this was based on a 
single study.53 54
In studies of patients with CKD stages 3 and 4, there was 
a marginally higher benefit to those taking the lipid-mod-
ifying drugs (figure 3), as the endpoint eGFR was 4% 
higher (ROM 1.04, 1.00 to 1.08, statistically significant, 
I2=88; STATA’s metaninf command produced output that 
indicated that the lower confidence bound was 1.0001 to 
4 decimal places) with a prediction interval of 0.91–1.18. 
This result was not robust as the results of sensitivity anal-
ysis were variable (online supplementary material). The 
high degree of heterogeneity was attributed to the Study 
of Heart and Renal Protection102–104 of the CKD stage 4 
subgroup, as removing this study reduced I2 from 88.3% 
to 45.3%. The intervention for this study was a higher dose 
of statin than in the other studies, and another lipid-mod-
ifying drug, ezetimibe, was also used. Adding data from 
the studies of patients including those with CKD stages 1 
and/or 2 increased the benefit to the intervention group 
but not significantly, and there was substantial heteroge-
neity between studies (I2=98%). Three trials had non-pla-
cebo controls (ASUCA,48 MEGA49–51 and GREACE76 77).
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Figure 3 ROM of estimated glomerular filtration rate at the 
end of the trials for lipid-modifying drugs versus comparator 
(boxes) and pooled estimates across studies (diamonds) 
calculated by the random-effects DerSimonian and Laird 
method, split by CKD stage. ASCOT-LLAa, atorvastatin and 
amlodipine versus placebo and amlodipine; ASCOT-LLAb, 
atorvastatin and atenolol versus placebo and atenolol; GISSI-
HFa, CKD stage 3; GISSI-HFb, CKD stage 4; GREACEa, 
atorvastatin versus usual care for the group with metabolic 
syndrome; GREACEb, atorvastatin versus usual care for the 
group without metabolic syndrome; SHARPa, CKD stages 
1–3; SHARPb, CKD stage 4. CKD, chronic kidney disease; 
ROM, ratio of means; SHARP, Study of Heart and Renal 
Protection.
Figure 4 ROM of estimated glomerular filtration rate at 
the end of the trials for glycaemic control drugs versus 
comparator (boxes) and pooled estimates across studies 
(diamonds) calculated by the random-effects DerSimonian 
and Laird method, split by CKD stage. Bode 2015L, 
intervention is low-dose canagliflozin (100 mg per day); Bode 
2015H,intervention is high-dose canagliflozin (300 mg per 
day); EMPA-REG H, intervention is high-dose empagliflozin 
(25 mg daily); EMPA-REG L, intervention is low-dose 
empagliflozin (10 mg daily); Kohan 2014L, intervention is low-
dose dapagliflozin (5 mg per day); Kohan 2014H, intervention 
is high-dose dapagliflozin (10 mg per day); CANVASa, CKD 
stage 3a; CANVASb, CKD stage 3b; TECOSa, CKD stage 3a; 
TECOSb, CKD stage 3b. CKD, chronic kidney disease; ROM, 
ratio of means.
There was a significant benefit to those taking 
glycaemic controlling drugs (figure 4) as the mean eGFR 
at the end of the study was 6% higher in the intervention 
group (ROM 1.06, 1.02 to 1.10). Heterogeneity between 
studies was low (I2=0%), yielding a prediction interval 
of 1.01–1.11. Sensitivity analyses showed that this result 
was robust (online supplementary material). Adding the 
CKD stage 1–4 studies, there was no significant difference 
between the intervention and comparator groups, and 
the heterogeneity between studies was high (I2=85%). In 
all studies the comparator groups received placebo drugs. 
We assessed the outlier41–43 as having high attrition bias, 
as of the 1887 who were randomised only 487 completed 
the 104-day study period. After excluding this study, there 
was a significant benefit to the intervention group, which 
was similar to that for the studies of patients with CKD 
stages 3 and 4.
A study64 65 of patients with CKD stage 3 reported a 22% 
higher endpoint eGFR from taking sodium bicarbonate 
(ROM 1.22, 1.10 to 1.36). Another study13 of patients 
with CKD stage 4 reported that taking sodium bicar-
bonate produced no significant effect on renal function 
in terms of CrCl (ROM 0.94, 0.85 to 1.05). Pooling these 
data, there was no significant treatment effect based on 
renal function (online supplementary material). In both 
studies the comparator groups received routine care.
Figure 5 summarises the effects of treatment on renal 
function by drug class for the four drug classes.
The GRADE confidence in these estimates was very low 
for our analysis of antihypertensive drugs, lipid-regulating 
drugs and sodium bicarbonate, and low for our analysis of 
glycaemic control drugs.
Proteinuria
Data pooling for proteinuria was possible only for antihy-
pertensive drugs in five studies. For studies of CKD stages 
3 and 4 and overall, there was no significant treatment 
effect (online supplementary material), with ROM of 
0.91 (0.78 to 1.05) and low heterogeneity at 41.3%. All 
sensitivity analyses produced the same result of no treat-
ment effect with low heterogeneity (online supplemen-
tary material).
Two studies of lipid-modifying drugs presented protein-
uria. The ATIC study73 of patients with CKD stages 2–4 
reported that treatment reduced urinary albumin excre-
tion and provided medians and ranges of the AER (77, 
3–2509 mg/24 hours for the intervention group, and 107, 
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Figure 6 Relative risk (RR) of cardiovascular disease during 
trials of lipid-modifying drugs versus comparator (boxes) and 
pooled estimates across trials (diamonds) calculated by the 
random-effects DerSimonian and Laird method, split by CKD 
stage. GREACEa, atorvastatin versus usual care for the group 
with metabolic syndrome; GREACEb, atorvastatin versus 
usual care for the group without metabolic syndrome. CKD, 
chronic kidney disease.
Figure 5 Effect of treatment on estimated glomerular 
filtration rate by drug class: CKD stages 3 and 4 only. ROM 
>1 favoured the intervention group (higher values are better). 
‘Studies’ refers to the study of different populations. Of the 
35 included studies, 15 reported renal function of patients 
with CKD stage 3 and/or stage 4. Of these, 9 reported renal 
function of a single population and 6 reported results for two 
CKD subgroups or dose-dependent subgroups. CKD, chronic 
kidney disease; ROM, ratio of means.
5–3545 mg/24 hours for the comparator group). The 
PREVEND IT lipid study67 of patients with CKD stages 
1–3 reported that treatment slightly increased urinary 
albumin excretion by quoting medians and IQRs (21.8 
and 11.6–41.9 mg/24 hours for the intervention group, 
and 20.3 and 12.5–40.5 mg/24 hours for the control 
group).
One glycaemic control study presented proteinuria as 
an outcome. The CANVAS programme19 20 reported that 
treatment significantly reduced albuminuria compared 
with the placebo group. ACR was expressed on the 
geometric mean scale, as 13% lower in the intervention 
group compared with the controls (95% CI 1% to 24%) 
in patients with CKD stage 3a, and 26% lower (95% CI 
20% to 31%) in patients with CKD stages 3b and 4.
One sodium bicarbonate study64 65 reported that treat-
ment lowered the ACR by quoting a median (IQR) of 
257.1 (205.5–305.0 mg/g creatinine) for the intervention 
group and 300.3 (241.8–347.5 mg/g creatinine) for the 
control group.
Adverse events
There were no significant differences in the risk of adverse 
events in the studies of antihypertensives, lipid-modi-
fying drugs and glycaemic control agents (online supple-
mentary material). Neither of the bicarbonate studies 
reported adverse events.
Maintenance dialysis and kidney transplantation
Two studies of antihypertensive drugs reported the 
number of patients who deteriorated and required 
maintenance dialysis or kidney transplantation. The risk 
in the intervention group was 31% lower than in the 
control group in the HALT PKD study52 of patients with 
stages 3 and 4 CKD (RR 0.69, 95% CI 0.50 to 0.96). In 
the RENAAL study,93–97 which was based on patients with 
CKD stages 2–4, treatment with antihypertensives led to 
a 23% reduction in risk of deterioration to kidney failure 
(RR 0.77, 95% CI 0.64 to 0.93). There were no significant 
differences in this outcome in the studies of lipid-mod-
ifying drugs or glycaemic control drugs (online supple-
mentary material).
Cardiovascular events
There were no significant differences between the inter-
vention and control groups in the risk of cardiovascular 
events in the studies of antihypertensives, whereas treat-
ment with lipid-modifying drugs led to a reduction in risk 
of 36% (RR 0.64, 95% CI 0.52 to 0.80, I2=30%) (figure 6). 
All the sensitivity analyses yielded similar results and 
heterogeneity generally remained low (online supple-
mentary material). The reduction in risk was slightly 
higher when data were added from the studies of patients 
that included those with CKD stages 1 and/or 2, but this 
reduction in risk was not significant (online supplemen-
tary material).
The TECOS glycaemic control study89 90 reported the 
number of patients who experienced cardiovascular 
events in patients with CKD stage 3. They reported no 
significant differences between the intervention and 
control groups (online supplementary material).
Mortality
In both our analyses of the studies of antihypertensive 
drugs and glycaemic control drugs, we found no signif-
icant differences, between the intervention and compar-
ator groups, in the risk of cardiovascular mortality and 
all-cause mortality (online supplementary material).
Two studies reported the effect of lipid-modifying drugs 
on the risk of cardiovascular mortality in patients with 
CKD stages 3 and 4. In the FIELD study,84–86 the risk was 
47% lower in the intervention group (RR 0.53, 95% CI 
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Figure 7 Relative risk (RR) of all-cause mortality during 
trials of lipid-modifying drugs versus comparator (boxes) and 
pooled estimates across trials (diamonds) calculated by the 
random-effects DerSimonian and Laird method, split by CKD 
stage. GREACEa, atorvastatin versus usual care for the group 
with metabolic syndrome; GREACEb, atorvastatin versus 
usual care for the group without metabolic syndrome. CKD, 
chronic kidney disease.
0.30 to 0.92), and in the AFCAPS/TEXCAPS study58–60 
there was no significant difference.
In the studies of patients with CKD stages 3 and 4 only, 
treatment with lipid-modifying drugs reduced the risk of 
all-cause mortality by 26% (RR 0.74, 95% CI 0.56 to 0.98) 
(figure 7 and online supplementary material).
DISCuSSIOn
Main findings
We found limited data on the effects of antihypertensive, 
lipid-modifying and glycaemic control drugs and sodium 
bicarbonate on the progression of renal function in 
patients with CKD stages 3 and 4. There was heterogeneity 
of patient populations in the included studies. Pooling 
data provided no pooled evidence of benefit or impair-
ment of renal function in these patients attributable to 
antihypertensive drugs. There was some suggestion of 
benefit to renal function from taking glycaemic control 
drugs and lipid-modifying drugs, and a clear reduction 
in cardiovascular disease and all-cause mortality by taking 
lipid-modifying drugs. There was insufficient evidence to 
draw any conclusions about sodium bicarbonate. There 
were only sufficient data to study the effects of antihyper-
tensive drugs on proteinuria and we found no significant 
treatment effect.
Comparison with other reviews
Our review is comparable with two reviews of drug inter-
ventions in patients with CKD, as they report changes in 
eGFR as outcome measures. Our findings on the protec-
tive effect of lipid-modifying drugs are consistent with 
the findings of Sandhu et al,9 who concluded that statins 
produce a small reduction in the progression of CKD 
in patients with cardiovascular disease. Our results are 
also consistent with those of Lewis et al,16 who reported 
the preliminary results of a review that considered the 
effect on kidney function of lowering low-density lipo-
protein cholesterol with statins. Their preliminary find-
ings suggested that for patients taking statins there was 
a highly significant reduction in the annual rate of CKD 
progression compared with control groups (based on the 
annual rate of change in eGFR). Both of these studies 
considered general populations with CKD. Our finding 
that lipid-modifying drugs reduce the risk of cardiovas-
cular events and all-cause mortality also concurs with 
other reviews of patients with CKD.108–110
Strengths and limitations
Our study is a first attempt to summarise the literature 
on drug treatment for patients with CKD types 3 and 4. 
We have identified, evaluated and compared the effects 
of different drug interventions on reducing the rate of 
CKD progression in patients with CKD stages 3 and 4. By 
focusing on this patient group, we took a primary care 
perspective on the management of CKD. Our search was 
extensive and comprehensive, with no restrictions on 
language or publication type. By using the ROM as the 
effect measure for continuous outcomes, we were able to 
pool data on different measures in a single analysis and 
overcome the limitations of the more established SMD. 
This provided an overall indication of the treatment 
effect, as did pooling data in cases where there were few 
studies or a high degree of heterogeneity. The generalis-
ability of our findings is limited by the paucity of studies, 
the high degree of statistical heterogeneity, and clinical 
heterogeneity in terms of comorbidities and treatment 
interventions. We concluded that clinical heterogeneity 
was inevitable in studies in these patients, as most were 
undergoing treatment with background medications. 
Paucity of data restricted our ability to explore the base-
line characteristics of studies and the effects of lipid-mod-
ifying drugs, glycaemic control drugs and bicarbonates, 
particularly on proteinuria and our other secondary 
outcomes. We were also restricted in our ability to investi-
gate the link between treatment effect and drug dose and 
assess publication bias fully. There was a wide variation 
of study characteristics (in terms of population size and 
follow-up period) and baseline characteristics (in terms 
of male/female split, smoking status, ethnicity and hyper-
tensive status). The generalisability of the findings is also 
limited by the effect of drugs on CKD being secondary 
in all the studies. For example, antihypertensives target 
hypertension and glycaemic control drugs target diabetes. 
Our ability to assess the quality of the included studies was 
restricted, because for nearly half the studies we could 
not assess allocation concealment bias, and for around a 
quarter of the studies we could not ascertain the risk of 
attrition bias or whether the participants, personnel and 
outcomes assessors had been blinded. Further bias may 
have arisen as most of the reports in our included studies 
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were subgroup or post-hoc analyses of trials. The balance 
achieved by randomising the whole trial population may 
not apply to subgroups of patients. However, we were 
unable to check this as few of these studies reported the 
necessary baseline characteristics, split by intervention 
group. Few studies reported the use of maintenance dial-
ysis and kidney transplantation, which may be considered 
to be more appropriate survival outcomes for patients 
with CKD stages 3 and 4, compared with mortality. Limita-
tions may also arise from the possible impact on patient 
management decisions following the introduction of CKD 
staging in 2002. Before that, patients were treated on the 
basis of the perceived cause of CKD rather than the CKD 
itself. A number of the included studies had recruitment 
periods that began before 2002, so their populations 
would be a mixture of patients managed under the old 
and new guidance. However, in spite of all these limita-
tions, the results of our analyses are consistent with those 
of other studies.
Implications for clinical practice and future research
In populations with CKD stages 3 and 4, lipid-modifying 
drugs and glycaemic control drugs may improve renal 
function, and lipid-modifying drugs are associated with a 
reduction in cardiovascular events. Although antihyper-
tensive drugs and sodium bicarbonate are presumed to 
reduce CKD progression,8 11–13 we did not find a signifi-
cant treatment effect. However, the paucity of data and 
high heterogeneity do not allow strong recommendations 
for clinical practice. Therefore, future research is needed 
into the effects of drugs on the progression in CKD, in 
particular in studies that focus on CKD progression as a 
primary outcome.
Our finding of limited data is important given that CKD 
is a common progressive disease. The drugs we consid-
ered are commonly used, but studies have concentrated 
on cardiovascular outcomes and not CKD outcomes.
COnCluSIOnS
This review suggests that glycaemic control and lipid 
regulation may improve renal function in patients with 
moderate CKD. There was no pooled evidence of either 
benefit or harm from antihypertensive drugs. However, 
the data were limited and heterogeneity was high for many 
of the analyses. Therefore, our findings are tentative.
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